EA201290040A1 - СПОСОБ ОЧИСТКИ ИНТЕРФЕРОНА-β - Google Patents

СПОСОБ ОЧИСТКИ ИНТЕРФЕРОНА-β

Info

Publication number
EA201290040A1
EA201290040A1 EA201290040A EA201290040A EA201290040A1 EA 201290040 A1 EA201290040 A1 EA 201290040A1 EA 201290040 A EA201290040 A EA 201290040A EA 201290040 A EA201290040 A EA 201290040A EA 201290040 A1 EA201290040 A1 EA 201290040A1
Authority
EA
Eurasian Patent Office
Prior art keywords
interferon
ifn
cleaning method
chromatography
anion
Prior art date
Application number
EA201290040A
Other languages
English (en)
Russian (ru)
Inventor
Штефан Арнольд
Кристиан Шекерман
Original Assignee
Байодженерикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байодженерикс Аг filed Critical Байодженерикс Аг
Publication of EA201290040A1 publication Critical patent/EA201290040A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EA201290040A 2009-07-07 2010-07-07 СПОСОБ ОЧИСТКИ ИНТЕРФЕРОНА-β EA201290040A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009032179A DE102009032179A1 (de) 2009-07-07 2009-07-07 Verfahren zur Reinigung von Interferon beta
PCT/EP2010/004130 WO2011003600A1 (en) 2009-07-07 2010-07-07 METHOD FOR THE PURIFICATION OF INTERFERON-β

Publications (1)

Publication Number Publication Date
EA201290040A1 true EA201290040A1 (ru) 2012-07-30

Family

ID=42562473

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290040A EA201290040A1 (ru) 2009-07-07 2010-07-07 СПОСОБ ОЧИСТКИ ИНТЕРФЕРОНА-β

Country Status (5)

Country Link
EP (1) EP2451470A1 (de)
JP (1) JP2012532167A (de)
DE (1) DE102009032179A1 (de)
EA (1) EA201290040A1 (de)
WO (1) WO2011003600A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795430C1 (ru) * 2019-07-18 2023-05-03 Абион Инк. Способ очистки дигликозилированного белка интерферон-бета

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564799A (en) 1978-11-07 1980-05-15 Toray Ind Inc Multi-stage concentration and purification of interferon originated from human fibroblast
CH648331A5 (de) 1979-07-31 1985-03-15 Hoffmann La Roche Homogenes fibroblasten-interferon und dessen herstellung.
US4278661A (en) 1979-10-12 1981-07-14 E. I. Du Pont De Nemours And Company Purification of interferon
NL7907791A (nl) 1979-10-23 1981-04-27 Stichting Rega V Z W Werkwijze voor het zuiveren van interferon.
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
DK170476B1 (da) 1980-04-03 1995-09-11 Biogen Inc Rekombinant DNA-molekyle, uni-cellulær vært transformeret med mindst ét rekombinant DNA-molekyle, fremgangsmåde til transformering af en uni-cellulær vært, samt fremgangsmåder til fremstilling af et polpeptid, der udviser den immunologiske eller biologiske aktivitet af human beta-interferon
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
JPS58201794A (ja) 1982-05-17 1983-11-24 Toray Ind Inc ヒトインターフェロンβの濃縮精製法
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
CA1231306A (en) 1983-03-03 1988-01-12 Erich Hochuli Purification of interferon
US4894330A (en) 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
IT1240612B (it) 1990-03-16 1993-12-17 Sclavo Spa Procedimento di purificazione del b-interferone umano ricombinante
DE4128319A1 (de) 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
TR199901968T2 (xx) 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
EP1224940B2 (de) 1997-09-23 2010-08-11 Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
SK286217B6 (sk) * 1998-04-28 2008-05-06 Laboratoires Serono Sa Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom
ITBO20010426A1 (it) 2001-07-06 2003-01-06 Alfa Wassermann Spa Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico
AU2003303635B2 (en) * 2002-12-26 2009-07-23 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
DK1917276T3 (en) * 2005-08-26 2018-05-07 Ares Trading Sa Process for Preparation of Glycosylated Interferon Beta
EP1960419B1 (de) * 2005-12-09 2016-03-16 Ares Trading S.A. Verfahren zur aufreinigung von fsh oder einer fsh-mutante
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
EP2245044A2 (de) * 2008-01-18 2010-11-03 F. Hoffmann-La Roche AG Reinigung nicht-glycosylierter proteine
DE102008051574A1 (de) * 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795430C1 (ru) * 2019-07-18 2023-05-03 Абион Инк. Способ очистки дигликозилированного белка интерферон-бета

Also Published As

Publication number Publication date
EP2451470A1 (de) 2012-05-16
DE102009032179A1 (de) 2011-01-13
JP2012532167A (ja) 2012-12-13
WO2011003600A8 (en) 2011-09-01
WO2011003600A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
SI1969127T2 (sl) Metoda pridobivanja biološko aktivnih proteinov, odvisnih od vitamina K, z rekombinantnimi metodami
BR112012011305A2 (pt) uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa
DK2046820T3 (da) Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf
WO2014178078A3 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
WO2005063820A3 (en) Il-7 fusion proteins
WO2013002580A3 (ko) 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
PE20150645A1 (es) Proteinas de fusion de interleuquina 10 y usos de las mismas
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BRPI0822775A2 (pt) Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa.
TR201901262T4 (tr) (2S,3R,4R,5S,6R)-2-(4-Kloro-3-(4-Etoksibenzil)Fenil)-6-(Metiltiyo)Tetrahidro-2H-Piran-3,4,5-Triol İçeren Bileşimler
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
EA201391489A1 (ru) Композиции со сниженной вязкостью
MX2013001447A (es) Metodo de produccion y purificacion de una sialiltransferasa soluble activa.
WO2011090719A3 (en) Protein purification by ion exchange
MX2019005999A (es) Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas.
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
WO2015021423A3 (en) Purification of chimeric fviii molecules
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
EA201691754A1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
MX2016002870A (es) Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
EA201290040A1 (ru) СПОСОБ ОЧИСТКИ ИНТЕРФЕРОНА-β
HU0402466D0 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
EA201270176A1 (ru) Производные тазаротена
WO2005073387A3 (de) Verfahren zur gewinnung von precursor z und seine verwendung zur herstellung eines mittels zur therapie humaner molybdäncofaktor-defizienz